Cuál es el precio por Hansa Biopharma AB (publ) (HNSA)

Precio por Hansa Biopharma AB (publ) (HNSA) es de$4.87

Cuál es la capitalización de mercado por Hansa Biopharma AB (publ) (HNSA)

Capitalización de mercado por Hansa Biopharma AB (publ) (HNSA) es $485.24M

Hansa Biopharma AB (publ) (HNSA) Ratio P/E

Hansa Biopharma AB (publ) is a biopharmaceutical firm dedicated to developing immunomodulatory therapies. Leveraging its unique enzyme technology platform, the company targets treatments that facilitate organ transplants and address rare autoimmune conditions driven by immunoglobulin G (IgG), alongside applications in gene therapy and cancer. Its primary drug candidate, Imlifidase, an enzyme therapy designed to cleave antibodies, is currently undergoing Phase 3 clinical trials for use in patients awaiting sensitized kidney transplants and those with anti-GBM antibody disease. Imlifidase is also in Phase 2 trials for treating antibody-mediated kidney transplant rejection and Guillain Barré syndrome. Further pipeline developments include NiceR (Novel immunoglobulin cleaving enzymes for Repeat dosing) for autoimmune diseases, transplantation, and oncology, as well as EnzE (Enzyme based antibody Enhancement) for cancer immunotherapy. Hansa Biopharma also has a preclinical research partnership with argenx BV, exploring the synergistic potential of their respective IgG-modulating technologies. Established in 2007, the company's headquarters are located in Lund, Sweden.

Año	Ratio P/E	Cambiar
Not enough data for the provided dates.

Año

Ratio P/E

Cambiar

Not enough data for the provided dates.

Empresa	P/E Ratio	Diferencia del P/E Ratio	País
Vertex Pharmaceuticals Incorporated VRTX.US	29.20	-	US
Argenx SE ARGX.US	30.62	-	NL
CSL Limited CSL.AX	32.46	-	AU
Moderna, Inc. MRNA.US	-7.93	-	US
Lonza Group AG LONN.SW	-	-	CH

Empresa

P/E Ratio

Diferencia del P/E Ratio

País